A Multicenter Retrospective Study on the Safety and Efficacy of the Surpass Evolve Flow Diverter System for the Treatment of Intracranial Aneurysms

In 132 patients with intracranial aneurysms treated with the Surpass Evolve flow diverter across three centers, complete occlusion reached 73.3% (88/120) with major stroke at 2.3% and no procedure-related mortality.

• Why it matters: Real-world evidence is needed to confirm whether the Surpass Evolve flow diverter maintains strong occlusion and safety outcomes outside controlled trials, and to identify factors linked to complete closure.
• What they did: A retrospective multicenter review enrolled patients treated between March 2023 and May 2024, assessing Raymond-Roy class 1 occlusion, periprocedural major stroke and mortality, follow-up mRS, imaging, and complications. Multivariate analysis tested predictors of complete occlusion.
• The result: Complete occlusion was independently predicted by not using an intraprocedural IIb/IIIa inhibitor and by absence of a branch arising from the aneurysm, and follow-up showed 96.9% with mRS 0–2.

AI summary of the abstract · may contain errors · not medical advice · read the paper.